RT Journal Article
T1 Vascular Endothelial Growth Factor as a Potential Biomarker of Neuroinflammation and Frontal Cognitive Impairment in Patients with Alcohol Use Disorder
A1 Requena-Ocaña, Nerea
A1 Flores-López, María
A1 Papaseit, Esther
A1 García-Marchena, Nuria
A1 Ruiz-Ruiz, Juan Jesús
A1 Ortega-Pinazo, Jesús
A1 Serrano, Antonia
A1 Pavón-Morón, Francisco Javier
A1 Farré, Magí
A1 Suárez-Pérez, Juan
A1 Rodriguez-de-Fonseca, Fernando
A1 Araos Gómez, Pedro Fernando
K1 Alcohol
AB (1) Background: Alcohol Use Disorder (AUD) is associated with functional disruption of several brain structures that may trigger cognitive dysfunction. One of the mechanisms of alcohol-associated cognitive impairment has been proposed to arise from its direct impact on the immune system, which culminates in the release of cytokines and chemokines which can eventually reach the brain. Alcohol can also disrupt the blood–brain barrier, facilitating the penetration of pro-inflammatory molecules throughout vascular endothelial growth factor A (VEGFA). Thus, alcohol-induced alterations in chemokines and VEGFA might contribute to the neuroinflammation and cognitive impairment associated with AUD. (2) Methods: The present cross-sectional study investigates whether patients with AUD (n = 86) present cognitive disability associated to alterations in plasma concentration of SDF-1, fractalkine, eotaxin, MCP-1, MIP-1α and VEGFA when compared to control subjects (n = 51). (3) Results: The analysis indicated that SDF-1 and MCP-1 concentrations were higher in AUD patients than in controls. Concentrations of VEGFA were higher in AUD patients with severe frontal deficits, and the score of frontal lobe functions was negatively correlated with VEGFA and fractalkine. Acute alcohol effects on VEGFA plasma levels in healthy volunteers demonstrated the induction of VEGFA release by heavy alcohol drinking. VEGFA was positively correlated with pro-inflammatory chemokines in AUD patients with frontal cognitive impairment. (4) Conclusions: we propose VEGFA/chemokine monitoring as biomarkers of potential cognitive impairment in AUD patients.
PB IOAP-MPDI
YR 2022
FD 2022-04-20
LK https://hdl.handle.net/10630/24635
UL https://hdl.handle.net/10630/24635
LA eng
NO Requena-Ocaña N, Flores-Lopez M, Papaseit E, García-Marchena N, Ruiz JJ, Ortega-Pinazo J, Serrano A, Pavón-Morón FJ, Farré M, Suarez J, Rodríguez de Fonseca F, Araos P. Vascular Endothelial Growth Factor as a Potential Biomarker of Neuroinflammation and Frontal Cognitive Impairment in Patients with Alcohol Use Disorder. Biomedicines. 2022; 10(5):947. https://doi.org/10.3390/biomedicines10050947
NO RETICS Red de Trastornos Adictivos, Instituto de Salud Carlos III (ISCIII), Ministerio deCiencia e Innovación and European Regional Development Funds—European Union (ERDF-EU)(RD16/0017/0001 and RD16/0017/003); ISCIII, ERDF-EU (PI20/01399, PI19/01577, PI19/00886);Ministerio de Sanidad, Delegación de Gobierno para el Plan Nacional sobre Drogas (PND 2020I048,PND 2019I040, PND 2018I044, PND 2018I033, PND 2016I024 and PND 2018I037) and Consejería deSalud y Familia, Junta de Andalucía (Neuro-RECA, RIC-0111-2019). F.J.P.-M. (CPII19/00022) andA.S. (CPII19/00031) hold “Miguel Servet II” research contracts from the National System of Health,ISCIII, ERDF-EU. F.J.P.-M. also holds a “Nicolas Monardes” contract from Servicio Andaluz de Salud,Consejería de Salud y Familia, Junta de Andalucía (C1-0049-2019). P.A. has a research contract(UMA-FEDERJA-076) funded by the Ministry of Economy and Knowledge—Regional Governmentof Andalucía and ERDF-EU. “PFIS” Predoctoral research contract (FI18/00249) financed by ISCIIIERDF/ESF and NGM has a ‘Sara Borrell’ Research Contract (CD19/00019) financed by ISCIII andERDF-EU. The funding sources had no further role in study design; in the collection, analysis, andinterpretation of data; in writing of the report; and in the decision to submit the paper for publication. Partial funding for open access charge: Universidad de Málaga
DS RIUMA. Repositorio Institucional de la Universidad de Málaga
RD 20 ene 2026